Endometriosis Market Set To Grow To Over $3bn By 2027

14 August 2018
Pharma

Visiongain has launched a new pharma report Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets

The migration of endometrial tissue outside the uterus to other parts of the body is called endometriosis. Rarely heard about, endometriosis is actually a common disease among women. Approximately,10% of women worldwide have endometriosis. The Diagnosis Survey of Endometriosis UK found that young girls and women are not aware of the fact that the pain and other symptoms they face are not normal.

Endometriosis is most commonly found on ovaries, fallopian tubes and the tissues lining the womb, which can lead to fertility problems. Other common places are around pelvis and abdomen such as vagina, bladder or bowel. Rarely, endometriosis can occur in other places such as lungs, brain or breast. Endometriosis affects women during their reproductive life (15-49 years of age). Normally during the menstrual cycle, the thickened womb lining will break down and blood will leave your body. However, in case of endometriosis, all other tissue which has moved outside the womb will also gets thickened and release blood with no route to escape the body. This can lead to pain, swelling and scarring. Endometriosis is a chronic inflammatory, oestrogen-dependent disease that grows with every menstrual cycle.

The real cause of endometriosis is unknown. There are many theories like retrograde menstruation, genetic predisposition, lymphatic or circulatory spread, immune dysfunction environmental causes and metaplasia but none fully explain why it occurs. Many organisations and societies all over the world are focusing in increasing the awareness and raising the funds to support women with endometriosis and this increasing recognition will grow the market over the next decade.

The lead visiongain report analyst for this report commented “Endometriosis is one of the most widespread chronic conditions in women affecting around 176 million of them around the world. Current diagnostic and treatment strategies possess limitations, reportedly causing side effects and inconvenience to patients. Many pharmaceutical companies are developing novel medicines with different therapeutic targets for treating endometriosis. The need for advances in medical technologies for better diagnoses and treatment for endometriosis expands, giving opportunities for companies and healthcare providers. A large population of affected women remain undiagnosed due to lack of knowledge about the disease. Better treatment of endometriosis depends on greater understanding of the disease in medical science and the pharma industry, as well as more awareness programmes by healthcare providers.”

Leading companies who are active in the Endometriosis market and are featured in the report include AbbVie, Pfizer, Bayer HealthCare, AstraZeneca, Astellas, Takeda, Repros Therapeutics, Euroscreen, Kissei Pharmaceutical and Addex Therapeutics

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031

Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.

13 November 2020

Read

Visiongain Publishes Antibacterial Drugs Market Report 2021-2031

The prevalence of bacterial diseases is significantly growing and expected to continuously rise over the forecast period. Number of bacterial diseases cases are increasing, like, bugs biting, including ticks, mosquitoes, lice and from an infected animal, contaminated food or water.

13 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever